GPT and fatty liver disease: In the most recent randomized, double-blind, placebo-controlled clinical trial examining the effects of empagliflozin on liver fat in patients with metabolic-dysfunction-associated steatohepatitis without diabetes mellitus, empagliflozin demonstrated a greater median reduction in MRI-Proton Density Fat Fraction (MRI-PDFF) (−2.49% vs. −1.43%; p = 0.025) and more significant reductions in hepatic steatosis, ALT, body weight, and ferritin, indicating the clinical potential of empagliflozin in non-diabetic metabolic-dysfunction-associated liver disease [131].